Conolidine’s analgesic outcomes stem from its interaction with non-opioid pain pathways. In contrast to opioids, which bind to µ-opioid receptors within the central nervous procedure, conolidine modulates alternate molecular targets. A Science Advances analyze discovered that conolidine interacts Along with the atypical chemokine receptor ACKR3/CXCR7, which regulates opioid peptide https://henryr986rtu8.wikiconversation.com/user